Enterovirus Infections is an indication for drug development with over 110 pipeline drugs currently active. According to GlobalData, preregistered drugs for Enterovirus Infections have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Enterovirus Infections compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Enterovirus Infections overview
Enteroviruses are a group of viruses that cause various infectious diseases, mostly affecting the respiratory and gastrointestinal systems. They are transmitted by contact with contaminated food, water, surfaces, or droplets. Enteroviruses are common in summer and fall and can affect people of all ages, but children are more susceptible. Most enterovirus infections are mild and self-limiting, but some can lead to serious complications such as meningitis, encephalitis, myocarditis, or poliomyelitis. Diagnosis is based on clinical symptoms and laboratory tests of blood, stool, throat, or cerebrospinal fluid samples. There is no specific treatment for enterovirus infections, only supportive care to relieve symptoms. Prevention measures include good hygiene practices, such as washing hands, disinfecting surfaces, and avoiding contact with sick people.
For a complete picture of PTSR and LoA scores for drugs in Enterovirus Infections, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
